Epstein-Barr virus-associated lymphoproliferation awareness in hemophagocytic syndrome complicating thiopurine treatment for Crohn's disease.
Serrate
C
C
Silva-Moreno
M
M
Dartigues
P
P
Poujol-Robert
A
A
Sokol
H
H
Gorin
N C
NC
Coppo
P
P
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D058846:Antibodies, Monoclonal, Murine-Derived; D001379:Azathioprine / Q000009:adverse effects*; D003424:Crohn Disease / Q000188:drug therapy*; D004359:Drug Therapy, Combination; D020031:Epstein-Barr Virus Infections / Q000139:chemically induced* / Q000188:drug therapy / Q000821:virology; D005047:Etoposide / Q000627:therapeutic use; D005260:Female; D005938:Glucocorticoids / Q000627:therapeutic use; D004854:Herpesvirus 4, Human / Q000302:isolation & purification*; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects*; D051359:Lymphohistiocytosis, Hemophagocytic / Q000139:chemically induced* / Q000188:drug therapy / Q000821:virology; D008232:Lymphoproliferative Disorders / Q000139:chemically induced* / Q000188:drug therapy / Q000821:virology; D008875:Middle Aged; D000069283:Rituximab
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D005938:Glucocorticoids; D007166:Immunosuppressive Agents; D000069283:Rituximab; D005047:Etoposide; D001379:Azathioprine